Merck KGaA’s $11.3bn Bio-Techne deal clears shareholder vote as life-science tools consolidation advances
Bio-Techne shareholders have approved Merck KGaA’s $11.3 billion cash acquisition, clearing a major hurdle in a transaction designed to expand the German group across multi-omics, spatial biology, precision diagnostics and cell therapy workflows.